Medical disclaimer
IRE With or Without NK Cell Therapy for Stage III/IV Pancreatic Cancer at Fuda
9 min read
Prepared by Bookimed editorial team
Medical content and care coordination

The source identifies treatment at the named clinic. Study results describe this cohort, not a predicted individual outcome.
Key takeaways
- The study compared IRE alone with IRE plus allogeneic NK cell infusion in 71 patients with unresectable stage III or IV pancreatic cancer.
- In stage III, median progression-free survival was 9.3 months with IRE plus NK cells and 8.1 months with IRE alone, and median overall survival was 13.2 versus 11.4 months.
- In stage IV, median overall survival was 9.8 months with IRE plus NK cells and 8.7 months with IRE alone.
- Adverse events were limited to grades 1 and 2, and fever was the most frequent.
- Follow-up was short (median 7.4 months), so these figures are early and cannot be used as a forecast for an individual patient.
The question this study addresses
Between July 2016 and May 2017, Fuda Cancer Hospital in Guangzhou enrolled 71 adults with unresectable stage III or IV pancreatic cancer. Stage III patients and stage IV patients were each split into those who had IRE only and those who had IRE plus allogeneic NK cell infusion. The authors looked at safety first, then at median progression-free survival (PFS), median overall survival (OS), response rate and disease control rate. The authors concluded that the combination increased median PFS and OS in stage III and extended median OS in stage IV. The patients were treated at Fuda Cancer Hospital, which is the same hospital as the clinic on this page.
- The situation
- Adults with pancreatic cancer at stage III or IV that could not be removed by surgery.
- The treatment
- IRE (a procedure that uses short electrical pulses on the tumor) alone, or IRE followed by infusions of allogeneic NK cells (immune cells from a donor), given as one course or three or more courses.
What this evidence cannot establish
- The abstract does not say whether the comparison was planned in advance or reviewed afterward, and the groups are small.
- Follow-up was short, with a median of 7.4 months, and the abstract does not say how many patients each adverse event percentage refers to.
- The study was run by doctors at the same hospital that offers the treatment, and Bookimed did not run or check the study.
Patient groups in the published study
17 patients · Published study group
Stage III pancreatic cancer treated with IRE alone
- Indication
- Stage III pancreatic cancer
- Treatment
- Irreversible electroporation (IRE) only
17 adults with stage III pancreatic cancer in the IRE-only group.
Stage III pancreatic cancer that could not be removed by surgery.
IRE alone, without NK cell infusion. This group served as the comparison for the IRE plus NK cell group.
Median progression-free survival (months)
8.1 months (median)
17 patients · Study group
median 7.4 months (3.6-11.2 months) for the series
Median overall survival (months)
11.4 months (median)
17 patients · Study group
median 7.4 months (3.6-11.2 months) for the series
Reported risks
- Study-wide only: adverse events in all patients were limited to grades 1 and 2, and fever was the most frequent. The abstract does not split these by group.
Limits of this evidence
- The abstract does not give response counts or the follow-up length for this group alone.
- The group is small, so its medians may change with more patients.
For a clinic assessment
- Imaging reports and the pathology report confirming the stage
- Current medication list and previous cancer treatment summary
15 patients · Published study group
Stage III pancreatic cancer treated with IRE plus allogeneic NK cells
- Indication
- Stage III pancreatic cancer
- Treatment
- IRE plus allogeneic natural killer (NK) cell infusion (8 patients had one course, 7 had 3 or more)
15 adults with stage III pancreatic cancer in the IRE plus NK cell group.
Stage III pancreatic cancer that could not be removed by surgery.
IRE followed by allogeneic NK cell infusion. 8 patients had one course and 7 had 3 or more courses.
Median progression-free survival (months)
9.3 months (median)
15 patients · Study group
median 7.4 months (3.6-11.2 months) for the series
Median overall survival (months)
13.2 months (median)
15 patients · Study group
median 7.4 months (3.6-11.2 months) for the series
Reported risks
- Study-wide only: adverse events in all patients were limited to grades 1 and 2, and fever was the most frequent. The abstract does not split these by group.
Limits of this evidence
- The abstract gives single-course versus multiple-course comparisons as medians only and does not say which subgroup size each median refers to.
- The abstract does not give response counts for this group.
For a clinic assessment
- Imaging reports and the pathology report confirming the stage
- Blood test results, including the tumor marker CA19-9 if available
22 patients · Published study group
Stage IV pancreatic cancer treated with IRE alone
- Indication
- Stage IV pancreatic cancer
- Treatment
- Irreversible electroporation (IRE) only
22 adults with stage IV pancreatic cancer in the IRE-only group.
Stage IV pancreatic cancer that could not be removed by surgery.
IRE alone, without NK cell infusion. This group served as the comparison for the IRE plus NK cell group.
Median overall survival (months)
8.7 months (median)
22 patients · Study group
median 7.4 months (3.6-11.2 months) for the series
Reported risks
- Study-wide only: adverse events in all patients were limited to grades 1 and 2, and fever was the most frequent. The abstract does not split these by group.
Limits of this evidence
- The abstract does not give median progression-free survival for stage IV.
- The abstract does not state the number of patients with disease control.
For a clinic assessment
- Imaging reports showing where the cancer has spread
- Pathology report and current medication list
17 patients · Published study group
Stage IV pancreatic cancer treated with IRE plus allogeneic NK cells
- Indication
- Stage IV pancreatic cancer
- Treatment
- IRE plus allogeneic natural killer (NK) cell infusion (9 patients had one course, 8 had 3 or more)
17 adults with stage IV pancreatic cancer in the IRE plus NK cell group.
Stage IV pancreatic cancer that could not be removed by surgery.
IRE followed by allogeneic NK cell infusion. 9 patients had one course and 8 had 3 or more courses.
Median overall survival (months)
9.8 months (median)
17 patients · Study group
median 7.4 months (3.6-11.2 months) for the series
Reported risks
- Study-wide only: adverse events in all patients were limited to grades 1 and 2, and fever was the most frequent. The abstract does not split these by group.
Limits of this evidence
- The abstract does not give median progression-free survival for stage IV.
- The abstract does not state the number of patients with disease control.
For a clinic assessment
- Imaging reports showing where the cancer has spread
- Pathology report and summary of previous treatment
Results and limits of the study
In stage III, median PFS was 9.3 months with IRE plus NK cells and 8.1 months with IRE alone, and median OS was 13.2 versus 11.4 months. In stage IV, median OS was 9.8 months with IRE plus NK cells and 8.7 months with IRE alone. The authors reported that multiple NK infusions were associated with better prognosis in stage III. These are group medians from a short follow-up, not a forecast for any one patient.
Risks reported by the source
- Adverse events in all patients were limited to grades 1 and 2, and fever was the most frequent. The abstract does not say how many patients each reported percentage refers to.
Limitations and unknowns
- The abstract does not say whether the study was planned in advance or reviewed afterward.
- Response counts are not given for each group.
- Median PFS for stage IV is not stated.
- Follow-up was short, so long-term results are unknown.
What to clarify in your treatment plan
Before booking, ask Fuda Cancer Hospital whether your stage and scans are similar to the patients described in the study. Ask how many NK cell courses would be planned and what they involve in practice. Also ask which records the team needs to review your case and what follow-up they arrange after the procedure.
Fuda Cancer Hospital: clinic profile
- The study patients were treated at Fuda Cancer Hospital, School of Medicine, Jinan University, Guangzhou. That is the same hospital as the clinic on this page, not a different one.
- The clinic profile for Fuda Cancer Hospital is available on Bookimed.

Xu Kecheng: doctor profile
- Niu Lizhi is listed as an author of the study with an affiliation to Fuda Cancer Hospital and Fuda Cancer Institute in Guangzhou.
- Xu Kecheng is also listed as an author with the same Fuda Cancer Hospital and Fuda Cancer Institute affiliations.
Safety and recovery: general information
General patient guidance, provided separately from the case evidence. Follow your treating team's instructions.
Possible side effects
- Procedures of this type in advanced pancreatic cancer may cause complications such as infections, gastrointestinal bleeding and fluid build-up in the abdomen (ascites).
Ask the clinic which of these it watches for and how it treats them.
- Blood clots may form in vessels inside the abdomen, including the mesenteric vessels.
Ask whether clot risk is checked before and after the procedure.
- Intestinal obstruction and injury to the pancreatic duct can occur.
Report new vomiting, severe belly pain or bloating to the team right away.
Recovery and aftercare
- Gastrointestinal and mesenteric bleeding may start late, during recovery, from 1 to 4 weeks after surgery.
Ask how you can reach the team during those weeks and what signs to watch for.
Suitability and cautions
- Heart rhythm problems may be a particular concern in people with existing heart conditions or an implanted pacemaker.
Tell the clinic about any heart condition or pacemaker before planning.
When to contact the clinic
- Signs of bleeding, which may appear late in recovery, from 1 to 4 weeks after surgery.
Contact the clinic or emergency services promptly if you notice black stools, vomiting blood or sudden weakness.
Request a personal plan from the clinic
Ask Fuda Cancer Hospital about IRE (NanoKnife) with or without NK cell therapy for stage III or IV pancreatic cancer
Send your diagnosis, stage and recent imaging to the Bookimed coordinator, who forwards them to Fuda Cancer Hospital for review. The clinic then tells you whether your case may fit this approach and what it would involve.
Ask the clinic for a current, itemized quotation. Published evidence does not establish package inclusions or a current price.
Frequently asked questions
Who ran this study and where were the patients treated?
Doctors at Fuda Cancer Hospital in Guangzhou ran the study, and the patients were treated there. The abstract names the setting as Fuda Cancer Hospital, School of Medicine, Jinan University, Guangzhou, which is the same hospital as the clinic on this page. Authors Niu Lizhi and Xu Kecheng list this hospital as their affiliation. Bookimed did not run the study and only summarized its published abstract.
What did the study compare?
It compared IRE alone with IRE plus allogeneic NK cell infusion in 71 adults with unresectable stage III or IV pancreatic cancer. Stage III patients and stage IV patients were each split into the two treatment groups. Some patients in the NK groups had one course of NK cells and others had 3 or more courses. The authors measured safety first, then survival and response.
How long did patients live without progression or overall?
In stage III, median PFS was 9.3 months with IRE plus NK cells and 8.1 months with IRE alone, and median OS was 13.2 versus 11.4 months. In stage IV, median OS was 9.8 months with IRE plus NK cells and 8.7 months with IRE alone. These are group medians after a short follow-up and are not a forecast for you.
Were there side effects?
Adverse events in all patients were limited to grades 1 and 2, and fever was the most frequent. The abstract also lists fatigue, nausea, pain at the puncture point and a temporary drop in blood pressure. It does not say how many patients each percentage refers to. Other published reports say that bleeding or clots may occur with IRE, so ask the clinic how it monitors for them.
Sources and scope
This page was prepared from the published abstract of the study, using a checked table of its groups and numbers. Safety points paraphrase separate medical sources and are marked as such.
- 1. Lin et al. – An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer.
Single-center comparative series: IRE alone versus IRE plus NK cells · 2017
71 adults with unresectable stage III or IV pancreatic cancer, treated between July 2016 and May 2017 at Fuda Cancer Hospital, Guangzhou.
Follow-up: Median 7.4 months (range 3.6-11.2 months)
Only the abstract was used, so details on methods, patient selection and the length of follow-up for each group are not available.
- 2. BMC Surgery (PMC), Xiang et al. 2025
- 3. Fuda Cancer Hospital on Bookimed
- 4. Xu Kecheng on Bookimed
- 5. Niu Lizhi on Bookimed
Scope and limitations
- A research summary is not an individual medical recommendation.
- Group results describe the study participants, not a forecast for any one patient.
Related procedures
About the editorial team

Prepared by
Bookimed editorial teamMedical content and care coordination
Bookimed prepares evidence summaries from published medical sources and anonymized care records. The clinic and any doctors named on this page are identified separately in their own sections.
